| Nov 8 |
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
|
| Nov 7 |
Ocugen Q3 2024 Earnings Preview
|
| Nov 7 |
Ocugen secures $30M debt funding
|
| Nov 7 |
Ocugen Secures $30 Million in Debt Funding
|
| Oct 31 |
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%
|
| Oct 28 |
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
|
| Oct 22 |
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
|
| Oct 17 |
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
|
| Oct 16 |
State Street Corp's Strategic Acquisition of Shares in Ocugen Inc
|
| Oct 10 |
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
|
